868858-12-2

Upstream product

• 868858-08-6 ([(6-benzyloxycarbonylamino-purin-9-yl)-acetyl]-{2-[2-(2-{2-[tert-butoxycarbonyl-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-acetylamino}-ethylamino)-acetylamino]-ethyl}-amino)-acetic acid methyl ester 
• 868858-10-0 {(2-{2-[allyloxycarbonyl-(2-{2-[tert-butoxycarbonyl-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-acetylamino}-ethyl)-amino]-acetylamino}-ethyl)-[(6-benzyloxycarbonylamino-purin-9-yl)-acetyl]-amino}-acetic acid methyl ester 
• 766548-75-8 [allyloxycarbonyl-(2-{2-[tert-butoxycarbonyl-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-acetylamino}-ethyl)-amino]-acetic acid 
• 868858-06-4 C₆₇H₇₄N₁₄O₁₄ 

Relevant academic research and scientific papers

A cyclic PNA-based compound targeting domain IV of HCV IRES RNA inhibits in vitro IRES-dependent translation

A cyclic molecule 1 constituted by a hepta-peptide nucleic acid sequence complementary to the apical loop of domain IV of hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA has been prepared via a 'mixed' liquid-phase strategy, which relies on easily available protected PNA and poly(2-aminoethylglycinamide) building blocks. This compound 1 has been elaborated to mimic 'loop-loop' interactions. For comparison, its linear analog has also been investigated. Although preliminary biological assays have revealed the ability of 1 to inhibit in vitro the HCV IRES-dependent translation in a dose-dependent manner, the linear analog has shown a slightly higher activity.